Olestra's effect on vitamins D and E in humans can be offset by increasing dietary levels of these vitamins.
One hundred two normal healthy males and females were given 0, 8, 20 or 32 g/d olestra to which had been added graded amounts of vitamins A, D and E for 8 wk in a parallel, double-blind study. The primary purpose of the study was to determine the amounts of vitamins D and E needed to offset the effect of olestra on the availability of these vitamins. Serum concentrations of retinol, carotenoids, 25-hydroxyvitamin D metabolites, alpha-tocopherol, phylloquinone, lipids, ferritin and total iron, iron-binding capacity and hematology parameters, plasma concentrations of des-gamma-carboxyprothrombin and prothrombin, and urinary gamma-carboxyglutamic acid (Gla) excretion were measured biweekly. Clinical chemistry and urinalysis parameters, vitamin B12 absorption, and serum 1,25-dihydroxyvitamin D concentration were measured at wk 0 and 8. Serum concentrations of alpha-tocopherol and 25-hydroxyergocalciferol were restored to control concentration by adding 2.1 mg d-alpha-tocopheryl acetate and 0.06 microg ergocalciferol per gram of olestra, respectively, to the diet. Olestra reduced serum concentrations of 25-hydroxyergocalciferol, carotenoids and phylloquinone in a dose-responsive manner but did not affect Gla excretion, plasma des-gamma-carboxyprothrombin and prothrombin concentrations, overall vitamin D status, vitamin B12 absorption or iron status. Laboratory evaluations showed no olestra-related effects. Subjects in all groups reported mild to moderately severe transient gastrointestinal symptoms. These symptoms did not affect study compliance or the integrity of the data.
Schlagheck
T G
TG
The Procter & Gamble Company, Winton Hill Technical Center, Cincinnati, OH, 45224, USA.
Kesler
J M
JM
Jones
M B
MB
Zorich
N L
NL
Dugan
L D
LD
Davidson
M H
MH
Peters
J C
JC
D015652:25-Hydroxyvitamin D 2 / Q000097:blood; D000328:Adult; D002112:Calcifediol / Q000097:blood; D003967:Diarrhea / Q000139:chemically induced; D004042:Dietary Fats, Unsaturated / Q000009:adverse effects / Q000494:pharmacology*; D004311:Double-Blind Method; D019358:Fat Substitutes / Q000009:adverse effects / Q000494:pharmacology*; D005227:Fatty Acids / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007501:Iron / Q000097:blood; D008297:Male; D009752:Nutritional Status / Q000187:drug effects*; D013395:Sucrose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D014807:Vitamin D / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000097:blood; D014810:Vitamin E / Q000008:administration & dosage* / Q000097:blood; D010837:Vitamin K 1 / Q000097:blood
D004042:Dietary Fats, Unsaturated; D019358:Fat Substitutes; D005227:Fatty Acids; D014807:Vitamin D; D014810:Vitamin E; D015652:25-Hydroxyvitamin D 2; D013395:Sucrose; C097949:1,25-dihydroxyvitamin D; C013692:sucrose polyester; D010837:Vitamin K 1; C104450:25-hydroxyvitamin D; D007501:Iron; D002112:Calcifediol